RNA binding motif protein 12Genealiases: HRIHFB2091 · SCZD19 · SWAN
Q-omics provides the consensus-scored RBM12 profile across patient tissues and cancer cell-line models. RBM12 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RBM12 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RBM12 protein abundance shows 29,833 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, HNSC, and LSCC as cancer lineages where RBM12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM12 survival associations across molecular data types. RBM12 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM12 RNA expression–survival associations across cancer types. High RBM12 expression shows unfavorable associations in LIHC, ACC and PAAD, but favorable associations in UCS, KIRC and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RBM12 RNA expression.
This table summarizes RBM12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RBM12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM12 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, STAD and COAD. The HNSC box plot shows higher RBM12 RNA expression in tumor versus normal tissue (log2 FC = +0.698, t-test p < 0.001).
This table shows molecular features associated with RBM12 in patient tissues and cancer cell lines. In patient samples, RBM12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
